Are androgen receptor variants a substitute for the full-length receptor?

Ji Lu, Travis Van Der Steen, Donald J. Tindall

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalNature Reviews Urology
Volume12
Issue number3
DOIs
StatePublished - Mar 11 2015

Fingerprint

Androgen Receptors
Castration
Prostatic Neoplasms
Androgens
Therapeutics
Ligands
Cell Line

ASJC Scopus subject areas

  • Urology

Cite this

Are androgen receptor variants a substitute for the full-length receptor? / Lu, Ji; Der Steen, Travis Van; Tindall, Donald J.

In: Nature Reviews Urology, Vol. 12, No. 3, 11.03.2015, p. 137-144.

Research output: Contribution to journalArticle

Lu, Ji ; Der Steen, Travis Van ; Tindall, Donald J. / Are androgen receptor variants a substitute for the full-length receptor?. In: Nature Reviews Urology. 2015 ; Vol. 12, No. 3. pp. 137-144.
@article{44fe159b7e9941d3acbcec6ab981b000,
title = "Are androgen receptor variants a substitute for the full-length receptor?",
abstract = "Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.",
author = "Ji Lu and {Der Steen}, {Travis Van} and Tindall, {Donald J.}",
year = "2015",
month = "3",
day = "11",
doi = "10.1038/nrurol.2015.13",
language = "English (US)",
volume = "12",
pages = "137--144",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Are androgen receptor variants a substitute for the full-length receptor?

AU - Lu, Ji

AU - Der Steen, Travis Van

AU - Tindall, Donald J.

PY - 2015/3/11

Y1 - 2015/3/11

N2 - Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

AB - Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

UR - http://www.scopus.com/inward/record.url?scp=84924533221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924533221&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2015.13

DO - 10.1038/nrurol.2015.13

M3 - Article

C2 - 25666893

AN - SCOPUS:84924533221

VL - 12

SP - 137

EP - 144

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 3

ER -